Skip to main content
Knowledge hub
Training

Grip Strength as a Mortality Biomarker: What the PURE Cohort Showed

Each 5 kg reduction in grip strength is associated with 16% higher all-cause mortality — a better predictor than blood pressure in the 140,000-person PURE cohort. Plus the clinical sarcopenia thresholds, what grip actually proxies for, and the training that builds it.

Share: 𝕏 f in
The PURE cohort and UK Biobank data on grip strength as a mortality biomarker, the clinical sarcopenia thresholds for adults, and the resistance-train

The 60-second version

Grip strength is one of the cheapest, most reliable, and best-validated biomarkers in clinical medicine. Across multiple large prospective cohorts, each 5 kg reduction in grip strength is associated with roughly 16% higher all-cause mortality, independent of age, smoking, exercise, and other obvious confounders. The biological reason: grip strength is a proxy for whole-body muscular function, which in turn reflects skeletal muscle mass, neurological function, and metabolic health. The clinical implications are increasingly being used: grip is now part of standard sarcopenia diagnosis, frailty screening in older adults, and pre-operative risk assessment. The practical implication for active adults: grip strength is trainable, and the biomarker effect appears causal (not just predictive) — resistance training that includes loaded carrying and hanging work appears to improve outcomes the grip biomarker correlates with.

The mortality data

The strongest single dataset is the PURE cohort — nearly 140,000 adults across 17 countries, followed for 4 years. The findings:

Follow-up data from PURE and from independent cohorts (UK Biobank, NHANES) has consistently replicated the finding. The dose-response curve is roughly linear — there’s no single “cliff” threshold; lower grip is uniformly worse Celis-Morales 2018.

“Grip strength is a better predictor of all-cause mortality than systolic blood pressure. The association is graded, dose-dependent, and persists after adjustment for major covariates. Grip strength deserves consideration as a routine clinical biomarker.”

— Leong et al., Lancet, 2015 view source

Why grip predicts so much

Grip isn’t magical — it’s a proxy for several underlying capacities that all matter for health:

What “weak grip” means

The clinical thresholds for sarcopenia (age- and sex-adjusted):

Grip is trainable

Unlike some biomarkers (chronological age, genetic markers), grip strength responds to training:

Is the effect causal?

The big remaining question in grip-mortality research is whether improving grip improves outcomes, or whether grip is just a marker of something else that improves outcomes. The trial evidence is suggestive but not definitive:

The current clinical consensus: train grip as part of general resistance training, not because grip-training in isolation extends life, but because the underlying capacity it reflects matters Celis-Morales 2018.

Practical takeaways

References

Leong 2015Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet. 2015;386(9990):266-273. View source →
Celis-Morales 2018Celis-Morales CA, Welsh P, Lyall DM, et al. Associations of grip strength with cardiovascular, respiratory, and cancer outcomes and all cause mortality: prospective cohort study of half a million UK Biobank participants. BMJ. 2018;361:k1651. View source →

Related reading